CIN No.: L24230TG1995PLC020093

Admn. Office & Factory: Survey No. 249, Brahmanapally Village, Hayathnagar Mandal, R.R.Dist. - 501 511. (T.S) INDIA. E-mail: concorddrugsltd@gmail.com Website: www.concorddrugs.in

To,

Date: 30.08.2022

BSE Limited P. J. Towers, Dalal Street Mumbai - 400001

Dear Sir/ Madam,

Sub: Outcome of 1st Extra-Ordinary General Meeting for the financial year 2022-23 held on

30.08.2022

Ref: Scrip Code: 538965

With reference to the subject cited above, this is to inform the Exchange that the 1stExtra-Ordinary General Meeting ofConcord Drugs Limitedfor the Financial Year 2022-23was held on Tuesday, 30.08.2022 at 11.00 a.m.through video conference/other audio-visual means.

In this regard, please find enclosed the following-

- (1) Summary of proceedings as required under Regulation 30, Part-A of Schedule -III of the SEBI (Listing Obligations and Disclosure Requirements) Regulations as **Annexure I.**
- (2) Voting Results as required under Regulation 44 of the SEBI (Listing Obligations and DisclosureRequirements) Regulations, 2015as **Annexure II.**
- (3) Report of Scrutinizer pursuant to Section 108 of the Companies Act, 2013 and Rule 20(4)(xii) of the Companies (Management and Administration) Rules, 2014 as **Annexure III.**

The Meeting concluded at 11:18a.m.

This is for the kind information and records of the Exchange, please.

Thanking you.

Yours sincerely, For Concord DrugsLimited

5. Many Rey

S. ManojKumar Reddy Whole-time Director DIN: 06991382

Encl. as above





Admn. Office & Factory: Survey No. 249, Brahmanapally Village, Hayathnagar Mandal, R.R.Dist. - 501 511. (T.S) INDIA. E-mail: concorddrugsltd@gmail.com Website: www.concorddrugs.in

To,

Date: 30.08.2022

BSE Limited P. J. Towers, Dalal Street Mumbai - 400 001

Dear Sir/ Madam,

Sub:

Proceedings of 1st Extra-ordinary General Meeting for Financial Year 2022-23held on Tuesday, 30.08.2022 at 11.00 a.m. through video conference as required under Regulation 30, PART - A of the schedule III of the SEBI (Listing Obligations and Disclosure Requirements), 2015

Ref:

Scrip Code: 538965

Summary of proceedings of the Extra-Ordinary General Meeting:

The 1stExtra-Ordinary General Meeting (EGM) of the Members of Concord Drugs Limited ('the Company') for Financial Year 2022-23was held on Tuesday, 30.08.2022 at 11.00 a.m. (IST) through Video conference /Other audio-visual means (OAVM), in compliance with general circularsissued by the Ministry of Corporate Affairs (MCA) and circulars issued by the Securities and Exchange Board of India (SEBI) in this regard and as per the applicable provisions of the Companies Act, 2013 and the Rules made thereunder.

Directors and KMPs present (all present through VC):

S.no	Name	Designation
1.	Mr. S. Nagi Reddy	Chairman and Managing Director
2.	Mr. S. Koni Reddy	Whole time Director & CFO
3.	Mr. S. Manoj Kumar Reddy	Whole time Director
4.	Mr. S. Nagavenkata Hareesh	Independent Director
5.	Mr. K. Ramachandra Reddy	Independent Director
6.	Ms. Sumeela Kasu	Independent Director

Other Invitees in attendance (present through VC):

S.no	Name	Designation
1.	Mr. Vivek Surana	Scrutinizer

Quorum of the Meeting:

A total of 34 members attended the meeting through VC. The meeting commenced at 11:00 a.m. and concluded at 11:18a.m.

Proceedings of the Meeting:

Mr. S. Manoj Kumar Reddychaired the meeting. He extended a warm welcome to all the shareholders, fellow Board members attending the meeting.

On ascertaining that the quorum being present and as per the instructions of the Chairman, Ms. Rajeshwari Reddy, moderator of the EGM proceeded with the meeting. She informed that the Company had provided the Members the facility to cast their vote electronically on the resolution set forth in the Notice. Members who were present at the EGM and had not casted their votes through remote e-voting were provided an opportunity to vote electronically at the EGM.

She thenproceeded with the agenda. She invited the members who had registered as speakers to speak / ask questions or express their views. The speaker shareholder's queries were answered satisfactorily.

The Board of Directors had appointed Mr. VivekSurana, Practicing Company Secretary as the Scrutinizer to scrutinize the process for remote e-voting & e-voting at EGM.

Ms. Rajeshwaribriefed the shareholders on the background of the resolution being put before them. Thereafter, she read the agenda item, i.e., appointment of Ms. Sumeela Kasu(DIN: 09571540) as an independent director of the Company for the information of the members.

Further, it was informed to the shareholders that the results of e-voting shall be disseminated to BSE Limited as soon as possible and the same will be placed on the website of the Company.

The meeting concluded at 11:18 a.m. after vote of thanks to the shareholders.

This is for the kind information and records of the Exchange, please.

Thanking you,

Yours sincerely, For Concord Drugs Limited

S. Manoj Kumar Reddy

S. Manoj Kumar Reddy Whole-time Director DIN: 06991382



General information about company				
Scrip code	538965			
NSE Symbol	336903			
MSEI Symbol				
ISIN	INFOSOT 01010			
Name of the company	INE858L01010			
Type of meeting	Concord Drugs Limited			
Date of the meeting / last day of receipt of postal ballot forms (in case of Postal Ballot)	EGM			
Start time of the meeting	30-08-2022			
	11:00 AM			
End time of the meeting	11:18 AM			

Scruti	inizer Details
Name of the Scrutinizer	Mr. Vivek Surana
Firms Name	Vivek Surana & Associates
Qualification	CS
Membership Number	24531
Date of Board Meeting in which appointed	06-08-2022
Date of Issuance of Report to the company	30-08-2022

Voting results	
Record date	23-08-2022
Total number of shareholders on record date	3133
No. of shareholders present in the meeting either in person or through prox	
a) Promoters and Promoter group	0
b) Public	0
No. of shareholders attended the meeting through video conferencing	10
a) Promoters and Promoter group	3
b) Public	31
No. of resolution passed in the meeting	
Disclosure of notes on voting results	1 Section 1 Section 1

				Resolution	(1)			
Resolution rec	uired: (Ordin	ary / Speci	al)	Special				
Whether promoter/promoter group are interested in the agenda/resolution?			No					
Description of resolution considered			APPOINTMENT O INDEPENDENT D	OF MS. SUM	EELA KA	SU (DIN: 09571540 DMPANY) AS AN	
Category	Mode of	No. of shares	No. of votes	% of Votes polled on outstanding	No. of votes – in	No. of votes –	% of votes in favour on votes	% of Votes against on votes

	voting	held	polled	shares	favour	against	polled	polled
		-(1)	(2)	(3)=[(2)/(1)]*100	(4)	(5)	(6)=[(4)/(2)]*100	(7)=[(5)/(2)]*100
	E-Voting	4284399	1991399	46.4802	1991399	0	100	0
Promoter and	Poll		0	0	0	0	0	
Promoter Group	Postal Ballot (if applicable)		0	0	0	0	0	0
	Total	4284399	1991399	46.4802	1991399	0	100	
	E-Voting				1331333	0	100	0
	Poll							
Public- Institutions	Postal Ballot (if applicable)	State						
	Total							
	E-Voting		250983	5.6282	250982	1	99,9996	0.0004
	Poll	1	0	0	0	0	0	0.0004
Public- Non Institutions	Postal Ballot (if applicable)	4459351	0	0	0	0		0 -
	Total	4459351	250983	5.6282	250982	1	99.9996	0.0004
	Total	8743750	2242382	25.6455	2242381	1		0.0004
				Whether res	solution is P		Yes	U
					of notes on		Textual Information	on(1)

	Text Block
Textual Information(1)	The votes include remote e-voting and venue voitng

Category	No. of Votes	
Promoter and Promoter Group	Two of votes	
Public Institutions		
Public - Non Insitutions	to the constitution and the constitution and	





FORM No. MGT-13 Report of Scrutinizer(s)

[Pursuant to Section 109 of the Companies Act, 2013 and Rule 21(2) of the Companies (Management and Administration) Rules, 2014]

To,

The Chairman,
1st Extra-Ordinary General Meeting for the FY 2022-23
Concord Drugs Limited
Survey No. 249,
Brahmanapally Village,
Hayatnagar Mandal,
R.R. Dist-501511, Telangana

Dear Sir/Madam,

Sub:

1st Extra-ordinary General Meeting for the FY 2022-23 of Equity Shareholders of Concord Drugs Limited held on Tuesday, 30.08.2022 at 11.00 a.m. (IST) through video conference (VC) /Other Audio-Visual Means (OAVM).

We, Vivek Surana and Associates, appointed as Scrutinizer for the purpose of scrutinizing e-voting process (remote e-voting and e-voting at general meeting) of the 1st Extra-Ordinary General Meeting (EGM) for the Financial Year 2022-23 in respect of the below mentioned resolution no. 1 of the Equity Shareholders of Concord Drugs Limited, held on Tuesday, 30.08.2022 at 11.00 a.m. (IST) through video conference (VC) /Other Audio-Visual Means (OAVM) and concluded at 11:18 a.m., submit our report as under:

- 1. In compliance with the provisions of Companies Act, 2013 and the Rules made there under relating to voting through electronic means (remote e-voting and e-voting at the general meeting) by shareholders on the resolution proposed in the Notice of the Extra-Ordinary General Meeting, our responsibility as a scrutinizer is to ensure that the voting process both through remote e-voting and e-voting at the general meeting are conducted in a fair and transparent manner and render Consolidated Scrutinizer's Report of the total votes cast in favor or against, if any, to Chairman of the meeting on the resolution, based on the reports generated from the electronic voting prior to the EGM (remote e-voting) and e-voting at EGM by electronic means (e-voting) system.
- 2. In accordance with the Notice of the Extra-Ordinary General Meeting dated 06.08.2022 sent to the shareholders and the Advertisement published pursuant to the Rule 20(3)(v) of the Companies (Management and Administration) Rules, 2014 on 07.08.2022 in "Financial Express" in English and "Prajasakti" in Telugu, the e-voting opened at 9.00 a.m. on 27.08.2022 and remained open up to 5.00 p.m. on 29.08.2022.

Plot No. 8-2-603/23/3, 2nd Floor, Banjara Hills, Road No. 10, Hyderabad - 500034, Telangana Ph: +91 9959581348, Email: viveksurana24@gmail.com

- The equity shareholders holding shares as on 23.08.2022 ("record date") were considered for purpose of voting on the resolution stated in the Notice of the Extra-Ordinary General Meeting of the Company.
- The e-voting results were unblocked on 30.08.2022 after the conclusion of EGM and the
 votes cast through e-voting at the EGM were unblocked in presence of two persons, who
 are not the employees of the Company.
- 5. The e-voting results/list of equity shareholders who have voted "for and against" were downloaded from the e-voting website of Central Depository Services (India) Limited (CDSL) (www.evotingindia.com) and the same were handed over to the Chairman of the meeting.
- 6. Based on the report generated from the electronic voting prior to the EGM (remote e-voting) and e-voting at EGM by electronic means (e-voting) system on the website of CDSL, the consolidated report on the results of the e-voting for the resolution is given here under:
- a) Resolution No.1: Appointment of Ms. Sumeela Kasu (DIN: 09571540) as an Independent Director of the Company:
- (i) Voted in favour of the resolution:

Mode of Voting	No. of Members Voted	Number of Votes cast in favour of the resolution	% of Total number of Valid Votes cast
Remote E- Voting	38	2242380	99.99992
Electronic voting (e-voting at the EGM)	1	1	0.00004
Total	39	2242381	99.99996

(ii) Voted against the resolution:

Mode of Voting	No. of Members Voted	Number of Votes cast against the resolution	% of Total number of Valid Votes cast 0.00004	
Remote E- Voting	1	1		
Electronic voting (e- voting at the EGM)	0	0	0.00	
Total	1	1	0.00004	



(iii) Invalid Votes:

Place: Hyderabad

Date: 30.08.2022

Mode of Voting	Total number of members (In person or by Proxy) whose votes were declared invalid	Total Number of Votes cast by them
Remote E- Voting	-	
Electronic voting (e- voting at the EGM)	-	-
Total	-	-

- 7. A soft copy containing a list of Equity shareholders who voted "FOR", "AGAINST" and those whose votes were declared invalid for the above said resolution is enclosed.
- 8. All the Electronic data and all other relevant documents relating to remote e-voting and e-voting at EGM shall remain in safe custody until the Chairman considers and approves and signs the minutes of the aforesaid EGM.

For Vivek Surana & Associates

Vivek Surana Proprietor

M. No.: A24531, CP No.: 12901 UDIN: A024531D000873491 Peer Review Cer No: 1809/2022